ArticleAbdominal radiology (New York)2025
US-Guided percutaneous core needle biopsy via the complete transhepatic approach: a reliable option for deep abdominal lesions.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Accuracy and safety of percutaneous CT-guided pancreatic biopsies.La Radiologia medica · 2025Article
- Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior.The American journal of case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the feasibility, reliability, and diagnostic performance of ultrasound (US)-guided percutaneous core needle biopsy (PCNB) performed via the complete transhepatic approach (CTHa) for abdominal lesions. MATERIALS AND
methodsThis study included 71 patients (31 males, 40 females) with a mean age of 64.8 ± 13.9 years (range: 19-93) who underwent US-guided PCNB via the CTHa for abdominal lesions between January 2014 and December 2024. All biopsies were performed by interventional radiologists with at least five years of experience using a coaxial system and an 18-gauge automatic biopsy device. Patients were assessed for technical success, diagnostic yield, and complications, which were classified as major or minor based on the Society of Interventional Radiology (SIR) guidelines.
resultsTissue samples were successfully obtained in all cases, achieving a 100% technical success rate. Adequate material for pathological diagnosis was available in 63 of 71 patients (88.7%), while a definitive diagnosis could not be established in 11.3% of cases. Diagnostic yield was significantly influenced by lesion type (solid or mixed with cystic components) and anatomical location (p = 0.001 and p = 0.032, respectively). Complications occurred in 12.7% of patients, including 11.3% minor and 1.4% major complications. Univariate logistic regression analysis identified a history of malignancy, lesion size along the biopsy path, and the length of liver parenchyma traversed as significant predictors of complications (p = 0.012, 0.027 and 0.003 respectively). In the multivariate model, liver parenchyma length remained the only independent risk factor (p = 0.023).
conclusionUS-guided PCNB via the CTHa is a safe and effective option for abdominal lesions when extrahepatic access is not feasible. While longer liver tissue traversal increases the risk of minor complications, no major adverse events were observed. Careful procedural planning and consideration of lesion location and cystic content are essential to optimize diagnostic yield.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.